

VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Madrid, Spain
20–22 June 2007

Abstracts

President

G Bonadonna (Milan, Italy)

Chairmen

H Cortés-Funes (Madrid, Spain)

L Gianni (Milan, Italy)

Scientific Committee

C Arteaga (Nashville, USA)

J Baselga (Barcelona, Spain)

P Conte (Modena, Italy)

H Cortés-Funes (Madrid, Spain)

L Gianni (Milan, Italy)

G Hortobagyi (Houston, USA)

C Hudis (New York, USA)

L Norton (New York, USA)

Faculty

A Antón (Zaragoza, Spain)

E Alba (Málaga, Spain)

C Arteaga (Nashville, USA)

J Baselga (Barcelona, Spain)

FA Calvo (Madrid, Spain)

LA Carey (Chapel Hill, USA)

E Ciruelos (Madrid, Spain)

R Colomer (Madrid, Spain)

P Conte (Modena, Italy)

H Cortés-Funes (Madrid, Spain)

M Cristofanilli (Houston, USA)

D Dershaw (New York, USA)

M Esteller (Madrid, Spain)

F Esteva (Houston, USA)

J Garber (Boston, USA)

L Gianni (Milan, Italy)

J Giralt (Barcelona, Spain)

A González (Madrid, Spain)

V Guillem (Valencia, Spain)

A Howell (Manchester, UK)

G Hortobagyi (Houston, USA)

C Hudis (New York, USA)

W Janni (Munich, Germany)

S Khan (Chicago, USA)

R Kramer (Houston, USA)

A Lluch-Hernández (Valencia, Spain)

F López-Ríos (Madrid, Spain)

EP Mamounas (Canton, USA)

M Martín (Madrid, Spain)

C Mendiola (Madrid, Spain)

R Noguero (Madrid, Spain)

L Norton (New York, USA)

R Orecchia (Milan, Italy)

EA Perez (Florida, USA)

J María Pérez Aznar (Madrid, Spain)

J-Y Petit (Milan, Italy)

L Pusztai (Houston, USA)

G Robb (Houston, USA)

JM San Román (Madrid, Spain)

I Smith (London, UK)

MJ Van de Vijver (Amsterdam, The Netherlands)

C Vázquez (Valencia, Spain)

J Antonio Virizuela (Sevilla, Spain)

E Winer (Boston, USA)

Contents

Speaker Abstracts

Introduction

- S1 Assessing prognosis for early breast cancer: clinical versus genetic profiles
GN Hortobagyi

SYMPOSIUM I

Prognostic and Risk Factors (Part I)

- S2 Circulating tumor cells as predictors of recurrence in primary breast cancer
W Janni
- S3 Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer
M Cristofanilli

Prognostic and Risk Factors (Part II)

- S4 Gene expression profiling for prognosis of breast cancer
M van de Vijver
- S5 Molecular and gene expression-based predictors of response to preoperative chemotherapy
L Pusztai
- S6 Role of MR and digital mammography for screening
DD Dershaw

SYMPOSIUM II

New Strategies for Primary Treatment (Part I)

- S7 Surgical issues in the breast and axillary nodes in patients treated with neoadjuvant systemic therapy
EP Mamounas
- S8 Treatment of the intact primary in women with metastatic breast cancer
SA Khan, H Hazard, D Scholtens
- S9 Immediate versus delayed breast reconstruction
GL Robb

New Strategies for Primary Treatment (Part II)

- S10 The nipple sparing mastectomy: a 5-year experience at the European Institute of Oncology of Milan
JY Petit, U Veronesi, R Orecchia, A Luini
- S11 Partial breast irradiation and intraoperative radiotherapy
R Orecchia

SYMPOSIUM III

Controversies in Clinical Practice (Part I)

- S12 Current status of adjuvant endocrine therapy for premenopausal patients with primary breast cancer
A Howell
- S13 Triple-negative (basal-like) breast cancer: a new entity
LA Carey

- S14 Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)
PF Conte, V Guarneri, C Bengala

- S15 Present and future role of bisphosphonates in treatment
GN Hortobagyi

SYMPOSIUM IV

Primary Systemic Therapy and Adjuvant Treatment

- S16 Standards and future strategies in adjuvant chemotherapy treatments
C Hudis, H McArthur
- S17 Adjuvant hormonal therapy for postmenopausal women
EP Winer
- S18 Preoperative systemic treatment for operable disease: biological correlates of response to neoadjuvant treatment
GN Hortobagyi
- S19 Neoadjuvant endocrine therapy: clinical and biological issues
IE Smith

SYMPOSIUM V

Advances in Metastatic Disease

- S20 Chemotherapy in metastatic disease: an overview
IE Smith

SYMPOSIUM VI

Targeted Therapy: Present and Future

- S21 Epigenetics of breast cancer
M Esteller
- S22 Present and future roles of bevacizumab in breast cancer
H Cortés-Funes
- S23 Novel strategies for HER-2-positive metastatic disease: mechanisms and therapeutic options to overcome trastuzumab resistance
FJ Esteva

Posters

- P1 Prognostic factors for the node-negative breast cancers
B-W Park, J-H Kim, K-S Kim, KS Lee
- P2 Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
F Carabantes-Ocón, E Saez-Lara, L Burgos-Garcia, E Villar-Chamorro, A Casaus-Hazañas, S Luna, C Martínez
- P3 Do breast cancer tumours downsize as well as downgrade with neoadjuvant chemotherapy?
M Dani, J McDonnell, S Karp, V Jaffe
- P4 Saline instillation into the cavity after conservation surgery for breast cancer is a safe way of improving cosmesis
M Dani, T Tahmid, J McDonnell, V Jaffe

- P5 A safety and efficacy study of bleomycin sulfate and electroporation in patients with metastatic or locally recurrent breast cancer**
V Paramanov, O Tyurin, S Polenkov, PM Goldfarb
- P6 Predictive value of HER2 expression for the selection of adjuvant chemotherapy in breast cancer patients**
A Hegmane, U Vikmanis
- P7 Axillary study before surgery in patients with breast cancer**
M Izquierdo, R Fabregas, J Feu, L Lopez Marin, B Navarro, C Ara, M Cusido, F Tresserra
- P8 Resveratrol downregulates acetyl-CoA carboxylase alpha and fatty acid synthase by activating AMP-activated protein kinase and suppressing the mammalian target of rapamycin signal pathway**
S Yoon, B-W Park, K-S Kim
- P9 Partial breast irradiation with an electron beam for patients submitted to conservative surgery**
MAC Maia, MM Netto, MS Maciel, JC Donoso, JV Salvajoli, ACA Pellizzon, RC Fogaroli, KW Bocalletti, C Tanous
- P10 Positive axillary lymph node metastases in T1-T3 breast cancer: prognostic value of extracapsular extension**
S Maksimovic, Z Gojkovic, M Opric
- P11 Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer**
S Menjón-Beltrán, R Olivencia-Dueso, E González-Jiménez, MJ Titos
- P12 Clinical role of trastuzumab in metastatic breast cancer: experience of a center**
S Menjón-Beltrán, R Olivencia, E Gonzalez
- P13 BRCA1a has antitumor activity in triple-negative breast cancers**
C Yuli, N Shao, G Oprea-Ilies, J Okoli, ESP Reddy, VN Rao
- P14 Diagnosis of familial breast cancer by multiplex PCR and clinical parameters**
H Rassi
- P15 Novel method of sentinel lymph node detection in malignant tumors using preparation 'UNIMAG'**
B Surguladze, Z Rati, T Tskitishvili
- P16 Frequency of febrile neutropenia in patients treated with taxane/epirubicine and colony-stimulating growth factors for breast cancer: comparison of filgrastim/lenograstim with pegfilgrastim**
W Schipping, R Holub, N Dandachi, T Bauernhofer
- P17 Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial**
I Sestak, R Edwards, A Howell, J Cuzick
- P18 Minimal residue disease (MRD)**
A Zaidi, G Tripuraneni, S Weller, B Ward, HD Sinnett, RC Coombes, MJ Slade

Proffered Papers

- P19 Algorithm for identification of individuals with hereditary predisposition to breast cancer and other breast cancer-associated forms of malignant neoplasms**
IV Zalutsky, NN Antonenkova, GM Porubova
- P20 Identification of individuals with hereditary predisposition to breast cancer and other breast cancer-associated forms of malignant neoplasms: data of the Belarusian Cancer Registry**
IV Zalutsky, NN Antonenkova
- P21 Tachosil® to reduce the morbidity of axillary lymph node dissection in breast cancer**
E Barranger, O Morel, G Akerman, C Malartic, D Clement
- P22 First clinical results on the potential of intraoperative imaging for sentinel lymph node biopsy in breast cancer**
E Barranger, K Kerrou, S Pitre, MA Duval, C Coutant, R Siebert, J Talbot, Y Charon, S Uzan
- P23 Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer**
V Guarneri, A Frassoldati, F Piacentini, K Cagossi, L Cavanna, A Michelotti, G Jovic, S Giovannelli, G Ficarra, C Oliva, P Conte
- P24 Significance of nuclear medicine: ^{99m}Tc-MDP in the detection of breast cancer bone metastasis**
P Karan, AN Tiwari, R Pisal

Index to authors